# Fujian Shengdi Pharmaceutical Co., Ltd.: Phase 2 study completed, 210 enrolled (Acute Ischemic Stroke)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. |
| NCT ID | NCT07233070 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Acute Ischemic Stroke |
| Intervention types | drug |
| Target enrollment | 210 |
| Site countries | China |
| Posted | 2025-11-18 |
| Planned start | 2025-10-31 |
| Event | Completed |
| Event date | 2026-09-17 |
| Last update posted | 2026-10-20 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 210 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07233070). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.